SCHEDULE 13D/A 0001727357 XXXXXXXX LIVE 3 Common Stock, $0.001 par value 01/28/2026 false 0001645469 61023L207 Monopar Therapeutics

1000 SKOKIE BLVD SUITE 350 WILMETTE IL 60091

Tactic Pharma LLC (847) 388-0349 c/o 1000 Skokie Blvd, Ste 350 Wilmette IL 60091 0001727357 N Tactic Pharma LLC OO N DE 0.00 0.00 0.00 0.00 0.00 N 0.0 OO REPORTING PERSON CONDUCTED A LIQUIDATING, PRO RATA DISTRIBUTION OF ISSUER STOCK TO ITS MEMBERS ON JANUARY 28, 2026. 0001727334 N Robinson Chandler OO N X1 307370.00 0.00 307370.00 0.00 307370.00 N 4.5 IN SOLE VOTING AND DISPOSITIVE POWER AND AGGREGATE AMOUNT INCLUDES 6,732 RESTRICTED STOCK UNITS SCHEDULED TO VEST WITHIN 60 DAYS AND 152,105 STOCK OPTIONS CURRENTLY EXERCISABLE OR SCHEDULED TO VEST AND BE EXERCISABLE WITHIN 60 DAYS 0001035909 N Brown Michael J OO N X1 124629.00 0.00 124629.00 0.00 124629.00 N 1.8 IN SOLE VOTING AND DISPOSITIVE POWER AND AGGREGATE AMOUNT INCLUDES 18,878 STOCK OPTIONS Common Stock, $0.001 par value Monopar Therapeutics 1000 SKOKIE BLVD SUITE 350 WILMETTE IL 60091 This Amendment No. 3 ("Amendment No. 3") amends and supplements the Schedule 13D filed with the Securities and Exchange Commission on December 23, 2019 (the "Initial Schedule 13D" and together with Amendment No. 1 filed on December 17, 2024 and Amendment No. 2 filed on September 24, 2025, the "Schedule 13D") by Tactic Pharma LLC ("Tactic Pharma"), Chandler Robinson and Michael Brown (the "Reporting Persons") with respect to the Common Stock, par value $0.001 per share, of Monopar Therapeutics Inc. (the "Issuer"). Capitalized terms used herein and not otherwise defined in this Amendment No. 3 shall have the meanings set forth in the Initial Schedule 13D. This Amendment No. 3 amends Item 1 and 5 to the extent set forth below. Refer to the cover pages. All percentages are calculated based on 6,682,584 shares of Common Stock outstanding as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 and filed with the Securities Exchange Commission on November 13, 2025. Refer to the cover pages. All percentages are calculated based on 6,682,584 shares of Common Stock outstanding as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 and filed with the Securities Exchange Commission on November 13, 2025. On January 28, 2026, Tactic Pharma conducted a liquidating, pro rata distribution of holdings of the Issuer's Common Stock to its members. Not applicable. As a result of the distribution described in Item 5(c) above, as of January 28, 2026, each of the Reporting Persons ceased to the beneficial owner of more than five percent of the Common Stock. The filing of this Amendment represents the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Persons. Tactic Pharma LLC /s/ Chandler Robinson 01/30/2026 Robinson Chandler /s/ Chandler Robinson 01/30/2026 Brown Michael J /s/ Michael Brown 01/30/2026